The Failure of Bans: A Convenience Store Owner's Perspective

Sep.05.2022
The Failure of Bans: A Convenience Store Owner's Perspective
Ali Haider, a convenience store owner and e-cigarette wholesaler, criticizes the FDA ban on menthol cigarettes, citing its negative impacts on businesses and encouraging harm reduction through THR strategies.

Ali Haider is a convenience store owner and electronic cigarette wholesaler with multiple businesses.


In April, the US Food and Drug Administration announced plans to ban menthol-flavored cigarettes. While some may see this decision as a breakthrough victory for public health, scholars caution that bans often fail. The menthol ban isn't focused on improving our communities or helping smokers transition to less harmful options; instead, it punishes those trying to quit while damaging local businesses.


As a convenience store owner and electronic cigarette wholesaler, my entire career has been spent in the retail industry. Over the years, I have seen numerous officials wrongly supporting similar policies, seemingly refusing to learn from the mistakes of their colleagues and predecessors. The same story continues to unfold - mandatory bans strip regulated products from businesses and fuel illegal trade.


A recent study by the Mackinac Center for Public Policy suggests that nearly 20% of all cigarettes consumed in Michigan are smuggled due to tax evasion or avoidance, ranking the state 15th in the nation for cigarette smuggling. In essence, over-taxing or banning certain cigarettes or other flavored nicotine products can lead to increased smuggling and further criminal activity.


In addition, convenience stores in Michigan typically rely on tobacco products for nearly 35% of in-store purchases. This figure does not include additional purchases made by these customers when visiting our stores. In other words, these businesses are not prepared to handle the significant losses resulting from the ban on all mint-flavored tobacco products.


Despite the Biden administration's efforts to provide special relief to local businesses across all industries, the ban has unfairly burdened convenience stores ravaged by the global pandemic. This is particularly true for stores in traditional minority communities, which often prefer menthol tobacco products.


There is a solution that can assist smokers in quitting called Tobacco Harm Reduction (THR). It aims to share potential public health and community benefits while providing smokers with opportunities and education on nicotine products with lower potential harm.


A recent study has found that the presence of e-cigarettes not only has little effect on encouraging young people to smoke, but also encourages more adults to quit smoking. Multiple studies have shown that nicotine substitutes, including e-cigarette products, are much safer than cigarettes because the tar in traditional cigarettes can lead to health problems, not nicotine.


I understand the benefits of switching firsthand, as I have implemented the THR strategy and transitioned from traditional cigarettes to e-cigarettes. Honestly, it's one of the best decisions I have ever made, which is why I can no longer remain silent about the FDA's attempts at regulation.


Unlike more advanced public health programs in Europe and elsewhere, the FDA lacks a tangible strategy or plan. While they may continue to support their ban on certain products, the reality remains that such an approach will only result in harmful outcomes. What we need from this administration are policies that support opportunities for those who want to quit smoking, not abandon smokers altogether.


The ban is a failed policy and history will continue to repeat itself until the FDA changes course.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truth or accuracy of the article content. The translation of this article is for industry communication and research purposes only.


Due to limitations in the level of translation, the translated article may not fully match the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.


The compilation of this information is the property of the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
Bret Koplow, acting director of the U.S. Food and Drug Administration's Center for Tobacco Products, will deliver a keynote and participate in a fireside chat at the National Association of Tobacco Outlets' Sept. 29-30 conference in Washington. His appearance comes months after the FDA moved to accelerate PMTA reviews and introduced a more differentiated enforcement policy for certain unauthorized ENDS and oral nicotine pouch products. The agency also plans a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement under the May guidance. NATO says its membership includes more than 66,000 retail stores, making product-status transparency and enforcement boundaries directly relevant to the retail sector.
Aug.14
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China National Tobacco Corporation and several subsidiaries plan to invest a combined CNY 60 billion ($8.7 billion) in share placements by Industrial and Commercial Bank of China and Agricultural Bank of China as strategic investors. The agreements extend beyond equity investment to corporate governance, banking services and supply-chain finance. The filings also disclose 2025 data on China Tobacco’s tax and profit contributions and industry scale.
Sep.07
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22